These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10961689)

  • 1. Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.
    Vogt U; Falkiewicz B; Bielawski K; Bosse U; Schlotter CM
    Acta Biochim Pol; 2000; 47(1):157-64. PubMed ID: 10961689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer.
    Falkiewicz B; Schlotter CM; Bosse U; Bielawski K; Vogt U
    Acta Biochim Pol; 2000; 47(1):149-56. PubMed ID: 10961688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of a micromethod in ovarian cancer chemosensitivity testing in vitro].
    Liu S; Qian X; Peng Z; Wang H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):298-9, 312. PubMed ID: 12947719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of the adenosine triphosphate chemosensitivity assay for pre-therapeutic determination of the chemosensitivity of breast cancer cells in cell culture].
    Köchli OR; Sevin BU; Schär G; Haller U
    Geburtshilfe Frauenheilkd; 1995 Jan; 55(1):7-16. PubMed ID: 7705600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
    Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
    Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
    Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
    Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
    Shi W; Gu M; Liang L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis.
    Brandt B; Vogt U; Schlotter CM; Jackisch C; Werkmeister R; Thomas M; von Eiff M; Bosse U; Assmann G; Zänker KS
    Gene; 1995 Jun; 159(1):35-42. PubMed ID: 7607571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Sevin BU; Perras JP
    Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
    Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
    Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
    Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results.
    Koechli OR; Avner BP; Sevin BU; Avner B; Perras JP; Robinson DS; Averette HE
    J Surg Oncol; 1993 Oct; 54(2):119-25. PubMed ID: 8412158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
    Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
    Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay.
    Vogt U; Striehn E; Bosse U; Klinke F; Falkiewicz B
    Acta Biochim Pol; 1999; 46(2):299-302. PubMed ID: 10547031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
    Kurbacher CM; Cree IA
    Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
    Ling ZQ; Qi CJ; Lu XX; Qian LJ; Gu LH; Zheng ZG; Zhao Q; Wang S; Fang XH; Yang ZX; Yin J; Mao WM
    Acta Pharmacol Sin; 2012 Mar; 33(3):401-6. PubMed ID: 22286916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line.
    Fei R; Shaoyang L
    Gynecol Oncol; 2002 Apr; 85(1):40-4. PubMed ID: 11925118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.